Validation of the 21-Gene Test as a Predictor of Clinical Response to Neoadjuvant Hormonal Therapy for ER+, HER2-negative Breast Cancer: The TransNEOS Study

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-018-4964-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evaluating the 21-Gene Assay Recurrence Score® as a Predictor of Clinical Response to 24 Weeks of Neoadjuvant Exemestane in Estrogen Receptor-Positive Breast Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2013English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Neoadjuvant Palbociclib on ER+ Breast Cancer (N007): Clinical Response and EndoPredict Value

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2018English

18f-Fluorodeoxyglucose (FDG) PET/CT After Two Cycles of Neoadjuvant Therapy May Predict Response in HER2-negative, but Not in HER2-positive Breast Cancer

Oncotarget
Oncology
2015English

Clinical Significance of Quantitative HER2 Gene Amplification as Related to Its Predictive Value in Breast Cancer Patients in Neoadjuvant Setting

OncoTargets and Therapy
OncologyPharmacology
2018English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

De-Escalated Therapy for HR+/HER2+ Breast Cancer Patients With Ki67 Response After 2 Weeks Letrozole: Results of the PerELISA Neoadjuvant Study

Annals of Oncology
MedicineOncologyHematology
2019English

Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study

Health
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy